ION expands ETF trading capabilities with Tradeweb integration
Patrick John Finn, President and COO of Twist Bioscience (NASDAQ:TWST), sold 2,240 shares of common stock on October 23, 2025, at a price of $30.875, totaling $69,160. The stock, currently trading at $34.18, has shown significant volatility this year with a 52-week range of $24.07 to $55.33. According to InvestingPro data, Twist Bioscience maintains strong liquidity with a current ratio of 3.9x.
Following the transaction, Finn directly owns 206,495 shares of Twist Bioscience. The sale was executed to cover tax withholding obligations related to the vesting of restricted stock units. With a market capitalization of $2.06 billion, analysts maintain a bullish outlook on TWST, as revealed in additional InvestingPro insights, which include 6 more key tips about the company’s prospects.
In other recent news, Twist Bioscience has partnered with Element Biosciences to launch a new sequencing workflow that significantly reduces sample processing time to as little as five hours. This development involves the Trinity Freestyle Fast Hybridization workflow, which integrates Twist’s library preparation kits with Element’s enrichment technology. Additionally, a Microsoft-led study, co-authored by Twist Bioscience, highlights potential biosecurity gaps in genetic screening due to AI-designed protein variants. This research underscores the need for updated biosecurity measures as AI technology advances.
In corporate governance news, Twist Bioscience has appointed Trynka Shineman Blake to its board of directors, where she will also serve on the audit committee. Blake brings extensive experience from her tenure as CEO of Vistaprint, where she significantly scaled the business. On the financial front, JPMorgan has lowered its price target for Twist Bioscience to $25 while maintaining an Underweight rating, citing the company’s leadership in synthetic biology. Meanwhile, TD Cowen has also reduced its price target to $36 but maintains a Buy rating, noting adjustments in the company’s fiscal year 2025 guidance due to changes in Next-Generation Sequencing revenue.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.